Carrimycin
drugOn this page
Also known as 4''-isovalerylspiramycin
Summary
Carrimycin (CHEMBL4650385) is a phase-3 clinical-stage unknown; indicated across 3 conditions including severe acute respiratory syndrome and oral cavity squamous cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650385 |
| Name | Carrimycin |
| Type | Unknown |
| Max phase | 3 |
Also known as: 4’’-isovalerylspiramycin, Carrimycin, CARRIMYCIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| oral cavity squamous cell carcinoma | 1 | MONDO:0004958 | EFO:0000199 |
| head and neck squamous cell carcinoma | 1 | MONDO:0010150 | EFO:0000181 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04286503 | PHASE4 | UNKNOWN | The Clinical Study of Carrimycin on Treatment Patients With COVID-19 |
| NCT04672564 | PHASE3 | TERMINATED | Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients |
| NCT04413214 | PHASE1 | COMPLETED | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial |
| NCT05988177 | Not specified | NOT_YET_RECRUITING | Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome